HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Lim, A. K. P. Articles by Taylor-Robinson, S. D. Search for Related Content PubMed PubMed Citation Articles by Lim, A. K. P. Articles by Taylor-Robinson, S. D. Social Bookmarking                      What's this? Hotlight (NEW!) What's Hotlight?

31P MR Spectroscopy in Assessment of Response to Antiviral Therapy for Hepatitis C Virus–Related Liver Disease

¹ Department of Imaging Sciences, Faculty of Medicine, Imperial College London, Robert Steiner MRI Unit, MRC Clinical Sciences Centre, Hammersmith Hospital, Du Cane Rd., London W12 0HS, United Kingdom.
² Liver Unit, Division of Medicine, Imperial College London, St. Mary's Hospital, London, United Kingdom.
³ Department of Medical Imaging, Faculty of Medicine, School of Medicine, Kaohsiung Medical University, Taiwan.
⁴ Department of Histopathology, Faculty of Medicine, Imperial College London, St. Mary's Hospital, London, United Kingdom.

OBJECTIVE. An increase in the ratio of phosphomonoester (PME) to phosphodiester (PDE) during ³¹P MR spectroscopy of the liver has been observed with increasing severity of hepatitis C–related liver disease. The purpose of this study was to investigate the utility of ³¹P MR spectroscopy as a biomarker of response to interferon and ribavirin treatment.

SUBJECTS AND METHODS. Forty-seven patients with biopsy-proven hepatitis C undergoing viral eradication treatment with interferon and ribavirin underwent hepatic ³¹P MR spectroscopy at 1.5 T (voxel size, 70 x 70 x 70 mm; TR, 10,000; number of signals averaged, 48). All underwent baseline imaging before treatment and repeated imaging at 6-month intervals after the start of treatment.

RESULTS. All patients underwent follow-up imaging 6 months after the start of treatment; 25 patients, 12 months; and 10 patients, 18 months after the start of treatment. According to the Ishak histologic scoring system, nine patients had mild hepatitis; 30 patients, moderate to severe hepatitis; and eight patients, cirrhosis. Thirty-two patients responded to antiviral treatment. Among these patients, 25 had a decrease in PME/PDE ratio on follow-up imaging. Among responders the mean baseline PME/PDE ratio decreased from 0.27 ± 0.02 (standard error) to 0.16 ± 0.01 after treatment (paired Student's t test, p < 0.001). Among the 15 virologic nonresponders, the ratios were similar in six patients; six other patients had an increase on follow-up imaging. In the latter nonresponder group, the mean baseline PME/PDE ratio was 0.21 ± 0.03 compared with 0.31 ± 0.08 after treatment (paired Student's t test, p =0.24).

CONCLUSION. The in vivo hepatic PME/PDE ratio decreased in patients with hepatitis C who responded to antiviral treatment and remained similar or increased in patients without a virologic response. These results suggest that PME and PDE can be used as biomarkers in a noninvasive test of response to treatment.

Keywords: hepatitis C • phospholipids • ³¹P MR spectroscopy

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?